UNSPSC 51151618: Ambutonium

This classification denotes an antimuscarinic agent with the molecular formula C20H27N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4O677EQ77U, chemically known as 4-dimethylamino-2,2-diphenylbutyramide but generally known as ambutonium, which bears US NIH Compound Identifier 8276. European Medicines Agency schedules Ambutonium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12844MIG. As of Q4 2014, AMBUTONIUM remains the US FDA Preferred Term for this commodity.

Ambutonium bears US NLM identifiers UMLS ID C0301368 and NCI Concept Code C79895. SMILES: CC[N+](C)(C)CCC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N.

UNSPSC 51151618 Ambutonium, a Commodity code, encompasses pharmaceutical products and drug-management systems that state and local governments procure to support public health and community safety initiatives. Based on recent solicitations, the code reflects actual purchasing of naloxone (an opioid overdose reversal agent) and drug deactivation systems for emergency response and harm-reduction programs, rather than a narrower pharmaceutical category alone. Issuing bodies under this code include county health departments and state health agencies; Seminole County, Florida and the Texas Health and Human Services Commission represent the recent activity in the opportunities block. Both buyers are sourcing products tied to substance-abuse response and pharmacy benefit management—county-level procurement for direct community health delivery and state-level sourcing for prescription and pharmaceutical program redesign.

Activity under the code appears concentrated in Florida and Texas. Seminole County issued an IFB (Solicitation IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building, with a two-year initial term and one-year renewal option, submitted electronically with all shipping and delivery costs included in bids. The Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to gather vendor capabilities and market intelligence on direct-to-manufacturer prescription programs and direct contracting outside traditional pharmacy benefit manager, group purchasing organization, and wholesaler channels, seeking vendor experience with self-insured employer and government sector contracting, negotiated net pricing, and outcomes-based agreements. The RFI is exploratory and designed to inform future formal solicitation strategy rather than commit to award amounts or timelines.